{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:43:39Z","timestamp":1761662619624,"version":"3.40.5"},"reference-count":54,"publisher":"American Academy of Pediatrics (AAP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5,1]]},"abstract":"<jats:p>OBJECTIVE. HIV-infected children are at high risk for bacteremia. Highly active antiretroviral therapy has reduced rates of opportunistic infections; less is known about its effect on pediatric bacteremia rates. Thus, we sought to determine its impact on bacteremia incidence in HIV-infected children.<\/jats:p>\n               <jats:p>METHODS. Children born during 1986\u20131998 were followed until 2004 in the Perinatal AIDS Collaborative Transmission Study. We determined the pre\u2013and post\u2013highly active antiretroviral therapy (before and after January 1, 1997) incidence of bacteremia among HIV-infected children and characterized the CD4% temporal declines and mortality among patients with and those without incident bacteremias.<\/jats:p>\n               <jats:p>RESULTS. Among 364 children, 68 had 118 documented bacteremias, 97 before and 21 after January 1, 1997. Streptococcus pneumoniae constituted 56 (58%) pre\u2013and 13 (62%) post\u2013highly active antiretroviral therapy cases. The incidence rate ratio of bacteremias comparing post\u2013versus pre\u2013highly active antiretroviral therapy was 0.3 overall and 0.2, 0.2, and 0.4 among children aged 0 to 24, 25 to 48, and 49 to 72 months, respectively. Kaplan-Meier analysis for time to first bacteremia in children born during the pre\u2013highly active antiretroviral therapy compared with the post\u2013highly active antiretroviral therapy era revealed that 69% and 94%, respectively, remained bacteremia free at a median follow-up of 6 years. The Cox proportional hazards model also showed a significant reduction of bacteremias in the post\u2013highly active antiretroviral therapy era, even after controlling for gender and race. Among children &amp;lt;6 years of age, those who experienced bacteremia had faster temporal CD4% decline than those who never had bacteremia. Survival analysis revealed that HIV-infected children with bacteremia experienced higher overall mortality when controlling for gender, race, and clinic site.<\/jats:p>\n               <jats:p>CONCLUSIONS. A significant decrease in bacteremia incidence and a prolongation in the time to first bacteremia incident were seen in the post\u2013highly active antiretroviral therapy era. Children with a steeper decline of CD4 T cells were more likely to develop bacteremia. Children who experienced bacteremia had an associated higher mortality than their bacteremia-free counterparts.<\/jats:p>","DOI":"10.1542\/peds.2007-0871","type":"journal-article","created":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T14:30:12Z","timestamp":1209652212000},"page":"e1229-e1239","source":"Crossref","is-referenced-by-count":18,"title":["Trends in Bacteremia in the Pre- and Post-Highly Active Antiretroviral Therapy Era Among HIV-Infected Children in the US Perinatal AIDS Collaborative Transmission Study (1986\u20132004)"],"prefix":"10.1542","volume":"121","author":[{"given":"Bill G.","family":"Kapogiannis","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Departments of Pediatrics"},{"name":"Medicine, Emory University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minn M.","family":"Soe","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Nesheim","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Departments of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin M.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Abrams","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Harlem Hospital Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Farley","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Maryland, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Medicine and Dentistry, Newark, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda J.","family":"Koenig","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bulterys","sequence":"additional","affiliation":[{"name":"Division of HIV\/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2008,5,1]]},"reference":[{"key":"2021120908264085300_R1","doi-asserted-by":"crossref","unstructured":"Hatherill M. Sepsis predisposition in children with human immunodeficiency virus. Pediatr Crit Care Med.\u20082005;6(3 suppl):S92\u2013S98","DOI":"10.1097\/01.PCC.0000161579.39050.6B"},{"key":"2021120908264085300_R2","doi-asserted-by":"crossref","unstructured":"Krasinski K, Borkowsky W, Bonk S, Lawrence R, Chandwani S. Bacterial infections in human immunodeficiency virus-infected children. Pediatr Infect Dis J.\u20081988;7(5):323\u2013328","DOI":"10.1097\/00006454-198805000-00006"},{"key":"2021120908264085300_R3","doi-asserted-by":"crossref","unstructured":"Bernstein LJ, Krieger BZ, Novick B, Sicklick MJ, Rubinstein A. Bacterial infection in the acquired immunodeficiency syndrome of children. Pediatr Infect Dis.\u20081985;4(5):472\u2013475","DOI":"10.1097\/00006454-198509000-00005"},{"key":"2021120908264085300_R4","doi-asserted-by":"crossref","unstructured":"Roilides E, Marshall D, Venzon D, Butler K, Husson R, Pizzo PA. Bacterial infections in human immunodeficiency virus type 1-infected children: the impact of central venous catheters and antiretroviral agents. Pediatr Infect Dis J.\u20081991;10(11):813\u2013819","DOI":"10.1097\/00006454-199111000-00004"},{"key":"2021120908264085300_R5","unstructured":"Ward JI, Zangwill KM. Haemophilus influenzae. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases. 4th ed. Philadelphia, PA: WB Saunders; 1998:1464\u20131482"},{"key":"2021120908264085300_R6","doi-asserted-by":"crossref","unstructured":"Espin Rios I, Garcia-Fulgueiras A, Navarro Alonso JA, et al. Seroconversion and duration of immunity after vaccination against group C meningococcal infection in young children. Vaccine.\u20082000;18(24);2656\u20132660","DOI":"10.1016\/S0264-410X(00)00062-1"},{"key":"2021120908264085300_R7","doi-asserted-by":"crossref","unstructured":"Sell SH, Wright PF, Vaughn WK, Thompson J, Schiffman G. Clinical studies of pneumococcal vaccines in infants. I. Reactogenicity and immunogenicity of two polyvalent polysaccharide vaccines. Rev Infect Dis.\u20081981;3(suppl):S97\u2013S107","DOI":"10.1093\/clinids\/3.Supplement_1.S97"},{"key":"2021120908264085300_R8","doi-asserted-by":"crossref","unstructured":"Leinonen M, Sakkinen A, Kalliokoski R, Luotonen J, Timonen M, Makela PH. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age children. Pediatr Infect Dis.\u20081986;5(1):39\u201344","DOI":"10.1097\/00006454-198601000-00008"},{"key":"2021120908264085300_R9","doi-asserted-by":"crossref","unstructured":"Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis.\u20081983;148(1):131\u2013137","DOI":"10.1093\/infdis\/148.1.131"},{"key":"2021120908264085300_R10","doi-asserted-by":"crossref","unstructured":"Ammann AJ, Schiffman G, Abrams D, Volberding P, Ziegler J, Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA.\u20081984;251(11):1447\u20131449","DOI":"10.1001\/jama.251.11.1447"},{"key":"2021120908264085300_R11","doi-asserted-by":"crossref","unstructured":"Clerici M, Stocks NI, Zajac RA, et al. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest.\u20081989;84(6):1892\u20131899","DOI":"10.1172\/JCI114376"},{"key":"2021120908264085300_R12","doi-asserted-by":"crossref","unstructured":"Roilides E, Clerici M, DePalma L, Rubin M, Pizzo PA, Shearer GM. Helper T-cell responses in children infected with human immunodeficiency virus type 1. J Pediatr.\u20081991;118(5):724\u2013730","DOI":"10.1016\/S0022-3476(05)80033-2"},{"key":"2021120908264085300_R13","doi-asserted-by":"crossref","unstructured":"Moir S, Malaspina A, Ogwaro KM, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA\u20082001;98(18):10362\u201310367","DOI":"10.1073\/pnas.181347898"},{"key":"2021120908264085300_R14","doi-asserted-by":"crossref","unstructured":"Lane HC, Fauci AS. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol.\u20081985;3:477\u2013500","DOI":"10.1146\/annurev.iy.03.040185.002401"},{"key":"2021120908264085300_R15","doi-asserted-by":"crossref","unstructured":"Moir S, Ogwaro KM, Malaspina A, et al. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci USA\u20082003;100(10):6057\u20136062","DOI":"10.1073\/pnas.0730819100"},{"key":"2021120908264085300_R16","doi-asserted-by":"crossref","unstructured":"Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med.\u20081983;309(8):453\u2013458","DOI":"10.1056\/NEJM198308253090803"},{"key":"2021120908264085300_R17","doi-asserted-by":"crossref","unstructured":"Bernstein LJ, Ochs HD, Wedgwood RJ, Rubinstein A. Defective humoral immunity in pediatric acquired immune deficiency syndrome. J Pediatr.\u20081985;107(3):352\u2013357","DOI":"10.1016\/S0022-3476(85)80505-9"},{"key":"2021120908264085300_R18","doi-asserted-by":"crossref","unstructured":"Schnittman SM, Lane HC, Higgins SE, Folks T, Fauci AS. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science.\u20081986;233(4768):1084\u20131086","DOI":"10.1126\/science.3016902"},{"key":"2021120908264085300_R19","unstructured":"Simpson BJ, Andiman WA. Difficulties in assigning human immunodeficiency virus-1 infection and seroreversion status in a cohort of HIV-exposed in children using serologic criteria established by the Centers for Disease Control and Prevention. Pediatrics.\u20081994;93(5):840\u2013842"},{"key":"2021120908264085300_R20","doi-asserted-by":"crossref","unstructured":"Peters VB, Hyatt AC, Schechter C, Diamant EP, Hodes DS. Evaluation of prophylaxis against invasive pneumococcal infections in human immunodeficiency virus-infected children. Pediatr Infect Dis J.\u20081994;13(7):667\u2013669","DOI":"10.1097\/00006454-199407000-00021"},{"key":"2021120908264085300_R21","doi-asserted-by":"crossref","unstructured":"Dankner WM, Lindsey JC, Levin MJ. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy. Pediatr Infect Dis J.\u20082001;20(1):40\u201348","DOI":"10.1097\/00006454-200101000-00008"},{"key":"2021120908264085300_R22","doi-asserted-by":"crossref","unstructured":"Andiman WA, Mezger J, Shapiro E. Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. J Pediatr.\u20081994;124(6):846\u2013852","DOI":"10.1016\/S0022-3476(05)83169-5"},{"key":"2021120908264085300_R23","doi-asserted-by":"crossref","unstructured":"Lichenstein R, King JC Jr, Farley JJ, Su P, Nair P, Vink PE. Bacteremia in febrile human immunodeficiency virus-infected children presenting to ambulatory care settings. Pediatr Infect Dis J.\u20081998;17(5):381\u2013385","DOI":"10.1097\/00006454-199805000-00007"},{"key":"2021120908264085300_R24","doi-asserted-by":"crossref","unstructured":"Farley JJ, King JC Jr, Nair P, Hines SE, Tressler RL, Vink PE. Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. J Pediatr.\u20081994;124(6):853\u2013858","DOI":"10.1016\/S0022-3476(05)83170-1"},{"key":"2021120908264085300_R25","doi-asserted-by":"crossref","unstructured":"Zangwill KM, Vadheim CM, Vannier AM, Hemenway LS, Greenberg DP, Ward JI. Epidemiology of invasive pneumococcal disease in southern California: implications for the design and conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis.\u20081996;174(4):752\u2013759","DOI":"10.1093\/infdis\/174.4.752"},{"key":"2021120908264085300_R26","doi-asserted-by":"crossref","unstructured":"Dagan R, Engelhard D, Piccard E, Englehard D. Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group. JAMA.\u20081992;268(23):3328\u20133332","DOI":"10.1001\/jama.268.23.3328"},{"key":"2021120908264085300_R27","doi-asserted-by":"crossref","unstructured":"Eskola J, Takala AK, Kela E, Pekkanen E, Kalliokoski R, Leinonen M. Epidemiology of invasive pneumococcal infections in children in Finland. JAMA.\u20081992;268(23):3323\u20133327","DOI":"10.1001\/jama.268.23.3323"},{"key":"2021120908264085300_R28","doi-asserted-by":"crossref","unstructured":"National Institute of Child Health and Human Development. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Study Group. N Engl J Med.\u20081991;325(2):73\u201380","DOI":"10.1056\/NEJM199107113250201"},{"key":"2021120908264085300_R29","doi-asserted-by":"crossref","unstructured":"Mofenson LM, Moye J Jr, Bethel J, Hirschhorn R, Jordan C, Nugent R. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 \u00d7 10(9)\/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. JAMA.\u20081992;268(4):483\u2013488","DOI":"10.1001\/jama.268.4.483"},{"key":"2021120908264085300_R30","doi-asserted-by":"crossref","unstructured":"Mofenson LM, Moye J Jr, Korelitz J, Bethel J, Hirschhorn R, Nugent R. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. Pediatr Infect Dis J.\u20081994;13(6):477\u20134784","DOI":"10.1097\/00006454-199406000-00003"},{"key":"2021120908264085300_R31","doi-asserted-by":"crossref","unstructured":"Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med.\u20081994;331(18):1181\u20131187","DOI":"10.1056\/NEJM199411033311802"},{"key":"2021120908264085300_R32","doi-asserted-by":"crossref","unstructured":"Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA.\u20081999;282(23):2220\u20132226","DOI":"10.1001\/jama.282.23.2220"},{"key":"2021120908264085300_R33","doi-asserted-by":"crossref","unstructured":"Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994\u201398: the EuroSIDA study. Lancet.\u20082000;356(9226):291\u2013296","DOI":"10.1016\/S0140-6736(00)02504-6"},{"key":"2021120908264085300_R34","doi-asserted-by":"crossref","unstructured":"Ledergerber B, Mocroft A, Reiss P, et al. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups. N Engl J Med.\u20082001;344(3):168\u2013174","DOI":"10.1056\/NEJM200101183440302"},{"key":"2021120908264085300_R35","doi-asserted-by":"crossref","unstructured":"Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med.\u20081998;338(13):853\u2013860","DOI":"10.1056\/NEJM199803263381301"},{"key":"2021120908264085300_R36","doi-asserted-by":"crossref","unstructured":"Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Intern Med.\u20082005;165(13):1533\u20131540","DOI":"10.1001\/archinte.165.13.1533"},{"key":"2021120908264085300_R37","doi-asserted-by":"crossref","unstructured":"Tumbarello M, Tacconelli E, Donati KG, et al. HIV-associated bacteremia: how it has changed in the highly active antiretroviral therapy (HAART) era. J Acquir Immune Defic Syndr.\u20082000;23(2):145\u2013151","DOI":"10.1097\/00042560-200002010-00006"},{"key":"2021120908264085300_R38","doi-asserted-by":"crossref","unstructured":"Redd SC, Rutherford GW 3rd, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis.\u20081990;162(5):1012\u20131017","DOI":"10.1093\/infdis\/162.5.1012"},{"key":"2021120908264085300_R39","doi-asserted-by":"crossref","unstructured":"Gona P, Van Dyke RB, Williams PL, et al. Incidence of opportunistic and other infections in HIV-infected children in the HAART era. JAMA.\u20082006;296(3):292\u2013300","DOI":"10.1001\/jama.296.3.292"},{"key":"2021120908264085300_R40","doi-asserted-by":"crossref","unstructured":"Resino S, Resino R, Maria Bellon J, et al. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Clin Infect Dis.\u20082006;43(2):243\u2013252","DOI":"10.1086\/505213"},{"key":"2021120908264085300_R41","doi-asserted-by":"crossref","unstructured":"Gray L, Newell ML, Thorne C, Peckham C, Levy J; European Collaborative Study. Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life. Pediatrics.\u20082001;108(1):116\u2013122","DOI":"10.1542\/peds.108.1.116"},{"key":"2021120908264085300_R42","doi-asserted-by":"crossref","unstructured":"Abrams EJ, Wiener J, Carter R, et al. Maternal health factors and early pediatric antiretroviral therapy influence the rate of perinatal HIV-1 disease progression in children. AIDS.\u20082003;17(6):867\u2013877","DOI":"10.1097\/00002030-200304110-00012"},{"key":"2021120908264085300_R43","doi-asserted-by":"crossref","unstructured":"Berk DR, Falkovitz-Halpern MS, Hill DW, et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA.\u20082005;293(18):2221\u20132231","DOI":"10.1001\/jama.293.18.2221"},{"key":"2021120908264085300_R44","doi-asserted-by":"crossref","unstructured":"Scott GB, Hutto C, Makuch RW, et al. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection. N Engl J Med.\u20081989;321(26):1791\u20131796","DOI":"10.1056\/NEJM198912283212604"},{"key":"2021120908264085300_R45","doi-asserted-by":"crossref","unstructured":"Freedman D, Koenig L, Wiener J, et al. Challenges to re-enrolling perinatally HIV-infected and HIV-exposed but uninfected children into a prospective cohort study: strategies for locating and recruiting hard-to-reach families. Paedr Perinat Epidemiol.\u20082006;20(4):338\u2013347","DOI":"10.1111\/j.1365-3016.2006.00742.x"},{"key":"2021120908264085300_R46","doi-asserted-by":"crossref","unstructured":"Bulterys M, Nesheim S, Abrams EJ, et al. Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study. Ann NY Acad Sci.\u20082000;918:212\u2013221","DOI":"10.1111\/j.1749-6632.2000.tb05491.x"},{"key":"2021120908264085300_R47","unstructured":"US Food and Drug Administration. Electronic orange book: approved drug products with therapeutic equivalence evaluations. Available at: www.accessdata.fda.gov\/scripts\/cder\/ob\/docs\/obdetail.cfm?Appl_No=020659&TABLE1=OB_Rx. Accessed September 3, 2005"},{"key":"2021120908264085300_R48","doi-asserted-by":"crossref","unstructured":"Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med.\u20082001;345(21):1522\u20131528","DOI":"10.1056\/NEJMoa011157"},{"key":"2021120908264085300_R49","unstructured":"Gahlinger PM, Abramson JH. Computer Programs for Epidemiologic Analysis [computer program]. PEPI Version 2. Stone Mountain, GA: USD, Inc; 1995"},{"key":"2021120908264085300_R50","doi-asserted-by":"crossref","unstructured":"Denny T, Yogev R, Gelman R, et al. Lymphocyte subsets in healthy children during the first 5 years of life. JAMA.\u20081992;267(11):1484\u20131488","DOI":"10.1001\/jama.267.11.1484"},{"key":"2021120908264085300_R51","unstructured":"Rothman K, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998"},{"key":"2021120908264085300_R52","unstructured":"U.S. Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. MMWR Recomm Rep.\u20081995;44(RR-7):1\u201315"},{"key":"2021120908264085300_R53","unstructured":"Recommendations of the U.S. Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR Recomm Rep.\u20081994;43(RR-11):1\u201320"},{"key":"2021120908264085300_R54","unstructured":"Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med.\u20081994;331(18):1173\u20131180"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/5\/e1229\/1175230\/zpe005080e1229.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/121\/5\/e1229\/1175230\/zpe005080e1229.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T02:50:57Z","timestamp":1639104657000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/121\/5\/e1229\/73451\/Trends-in-Bacteremia-in-the-Pre-and-Post-Highly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5,1]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2008,5,1]]},"published-print":{"date-parts":[[2008,5,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-0871","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2008,5,1]]}}}